

CV – Christoph Kraus, M.D., Ph.D.

*Research Psychiatrist – Neuroimaging LABs
Department of Psychiatry and Psychotherapy
Medical University of Vienna
Währinger Gürtel 18-20, 1090 Vienna, Austria
christoph.kraus@meduniwien.ac.at*

*Guest Researcher (Special Volunteer)
National Institute of Mental Health
Experimental Therapeutics and Pathophysiology Branch
National Institute of Health
10 Center Dr., Bethesda, MD 20814, USA
chistoph.kraus@nih.gov*

Education:

2002 – 2009 Undergraduate and graduate school: Medical University of Vienna
(founded: 1365)

Postgraduate Education:

2009 – present Research Scientist at the Neuroimaging Lab, Department of Psychiatry and Psychotherapy, Medical University of Vienna.

2012 – 2015 Ph.D. in Clinical Neurosciences (N790). Title: Serotonin and Neuroplasticity – Investigated in vivo by Positron Emission Tomography and structural Magnetic Resonance Imaging. Supervisor: Prof. Rupert Lanzenberger, Mentors: Prof. Siegfried Kasper, Prof. Wolfgang Wadsak

1.9.2011 – 01.3.2018 Clinical Training, Medical University of Vienna, Department of Psychiatry and Psychotherapy, attending psychiatrist.

1.10.2012 – 1.10.2013 Clinical Training, Medical University of Vienna with emphasis on treatment of forensic psychiatric patients in the federal prison “Justizanstalt Josefstadt”

1.3.2014 – 30.9.2014 Psychiatric Consultant Service at the Vienna General Hospital (AKH, ~1770 beds)

1.10.2014 – 1.4.2015 Training in Neurology, Department of Neurology, Medical University of Vienna, Prof. Auff

1.4.2017 – 31.9.2017 Training in Medicine – State Hospital Eisenstadt, Prof. Puespoeck

2013 – 2019 Training in Cognitive Behavioral Therapy

1.6.2018 – onwards Tenure track qualification for Assistant Professorship at the Medical University of Vienna

25.6.2018 – 15.7.2019 Postdoctoral Research Fellowship at the National Institute of Health (around EUR 71.000,- annually), Mentor: Prof. Carlos Zarate, Chief of the Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch (ETPB) at the NIMH

Further Education and Courses:

2009 Psychotherapeutic propaedeutics – H.O.P.P. Vienna

2012 Statistical Parametric Mapping Course, Center for Experimental Medicine, Department of System Neuroscience UKE Eppendorf, Hamburg.

2012 ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe

2015 ECNP Clinical Trials Workshop (Prof. Eduard Vieta)

2015 Targeted Network Meeting, ECNP, Amsterdam

2016 ECNP Brain Price Master Class (Prof. Trevor Robbins)

2019 AFNI Bootcamp

Practical knowledge of R, SPSS, Linux, AFNI, SPM, PMOD, Matlab (in order of actual skill).

Scientific Collaborations:

- 2009 – present staff member in the „NEUROIMAGING LABs (NIL)“, Department of Psychiatry and Psychotherapy, MUW. Collaboration and coinvestigator in clinical projects focused on neuroimaging.
- 2009 – 2011 Coinvestigator: Networks of Anxiety: Connectivity Analysis in Social Phobia using Functional Magnetic Resonance Imaging, OeNB procet number 12982, EK 619/2007, Principal Investigator: Assoc.-Prof. Priv.-Doz. Dipl.-Ing. Dr. Christian Windischberger, MUW Austria.
- 2009 – 2011 Coinvestigator: The influence of hormone replacement therapy on the cerebral serotonin-1A receptor distribution and mood in postmenopausal women. A longitudinal study using Positron Emission Tomography (PET) and the radioligand [carbonyl-¹¹C]WAY-100635. Principal Investigator: O. Univ. Prof. Dr. h.c. mult Dr. med. S. Kasper, MUW Austria.
- 2010 – 2011 Coinvestigator: Effects of electroconvulsive therapy on serotonin-1A receptor binding in major depression. A longitudinal study using Positron Emission Tomography (PET) and the radioligand [carbonyl-¹¹C]WAY-100635. Principal Investigator: Ao. Univ. Prof. Dr. Richard Frey, MUW Austria.
- 2012 – 2016 Coinvestigator: Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders (MAN-BIOPSY). Research cluster “Multimodal Neuroimaging in clinical neurosciences (MMI-CNS), Medical University Vienna, University of Vienna. Principal Investigators: Assoc.-Prof. Priv.-Doz. Dr. Rupert Lanzenberger, Univ. Prof. Mag. Dr. Claus Lamm, PhD
- 2016 – 2017 Principal Investigator: Brain glucose metabolism in healthy subjects and depressive patients during transcranial direct current stimulation
- 2018 – present Subinvestigator: Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist, PI: Dr. Carlos Zarate
- 2020 – present Principal Investigator: Glucose Consumption During Deep Brain Stimulation with Functional [¹⁸F]FDG-Brain-PET in Obsessive-Compulsive Disorder

Grants

- 2020-2022 NARSAD Young Investigator Grant: Glucose Consumption During Deep Brain Stimulation with Functional [¹⁸F]FDG-Brain-PET in Obsessive Compulsive Disorder. (EUR 62.765)

Universitary Teaching:

- Thesis Supervision Four completed undergraduate thesis supervisions.
- 2013 – present Lecturer in clinical psychiatry and psychopharmacology at the Medical University of Vienna (~70 lectures).
- 2014 – 2018 Nurse training in clinical psychiatry at the School of Nursery of the Vienna Hospital Association

Other Universitary Activities:

- 2012 – 2017 Representative of resident psychiatrists at the Department of Psychiatry and Psychotherapy
- 2016 - 2017 Teaching Coordinator at the Department of Psychiatry and Psychiatry, Medical University of Vienna

Memberships in Professional Societies:

European College of Neuropsychopharmacology (ECNP)
The International College of Neuropsychopharmacology (CINP)
Austrian Psychiatric and Psychotherapeutic Association (ÖGPP)
Austrian Pharmacological Society (APHAR)
Austrian Society for fMRI & Organization for Human Brain Mapping, Alpine Chapter
Austrian Medical Chamber

Reviewer for Manuscripts:

Ad hoc reviewer for Biological Psychiatry, Journal of Psychiatry and Neuroscience, Cerebral Cortex, Pharmaceuticals, World Journal of Biological Psychiatry, NeuroImage, International Journal of Neuropsychopharmacology, Journal of Affective Disorders, Psychiatry Research, Neuroscience and Biobehavioral Reviews, Molecular Neurobiology, BMC Psychiatry, Social Psychiatry and Psychiatric Epidemiology, Child Abuse and Neglect, Molecules and many others

Editorial Work:

Journal of Chronic Stress – Editor including deputy chief editorial work
BMC Psychiatry – Associate Editor, Mood Disorders

Prizes

2011	Best Poster Award, 7 th PhD Symposium MUW
2012	Best Poster Award, 8 th PhD Symposium MUW, Stipendiate for international Mobility by the Österreichische Forschungsgesellschaft (ÖFG)
2012	BSM – ÖGN – Mallinckrodt Förderungspreis for nuclear medicine
2014	Rafaelsen Young Investigator's award by the International College of Neuropsychopharmacology (CINP), Stipendiate for international Mobility by the Österreichische Forschungsgesellschaft (ÖFG)
2015	WFSBP Educational Grant
2015	ECNP Travel Award
2016	Rudolf Höfer Price for nuclear medicine
2020	SOBP International Travel Fellowship Award
2020	American Society of Clinical Psychopharmacology – New Investigator Award

Chairs at International Meetings:

Co-Chair, Serotonin and Neuroplasticity at the WFSBP Conference 2015
Young Programme Sub-committee for the Seoul Congress 2016
Brainstorming Session, ECNP-Congress Vienna 2016

Personal Statement:

I am a research psychiatrist with a scientific focus on improving biological assessment, diagnosis and therapy of mood disorders. I have been trained in clinical psychiatry at the Medical University of Vienna (Prof. Siegfried Kasper) and am currently an attending psychiatrist at the Department of Psychiatry and Psychotherapy. I am certified to practice cognitive behavioral therapy and to apply electroconvulsive therapy. As academic, I completed a PhD-thesis on serotonin and neuroplasticity at the Medical University of Vienna (Prof. Rupert Lanzenberger) working with PET and MRI. In addition, I conducted a postdoctoral research fellowship at the National Institute of Mental Health at Carlos Zarate's Lab working in resting state fMRI markers of Major Depressive Disorder. My current aims are to establish biological correlates and predictors of antidepressant treatment by leveraging multimodal imaging

methods such as PET and fMRI. Reliable markers are urgently needed to introduce staging models that will inform patients, their relatives and healthcare providers on disease severity and future outcomes of major depression.